Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | MPL | P40238 | 3/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936339 | 0.83 | TRPA1 (0.44) | KMOPDE3BPDE3AMAPK14MAPKAPK2 | |
| SCHEMBL2218335 | 0.81 | TRPA1 (0.43) | PDE3BPDE3A | |
| SCHEMBL1935744 | 0.81 | TRPA1 (0.43) | KMOPDE3BPDE3AMAPKAPK2 | |
| SCHEMBL2221769 | 0.81 | MPL (0.41) | MPLGRIN1GRIN2BMAPKAPK2 | |
| SCHEMBL1935091 | 0.81 | TGFBR1 (0.47) | KMO | |
| SCHEMBL2218705 | 0.81 | KDM4C (0.38) | PDE3BPDE3AMAPKAPK2 | |
| SCHEMBL2220256 | 0.81 | TGFBR1 (0.40) | KMOMPLPDE3BPDE3AGRIN1 | |
| SCHEMBL1935750 | 0.80 | KMO (0.45) | KMOGSK3BMAPK14 | |
| SCHEMBL1935549 | 0.79 | ALOX5AP (0.40) | PDE3BPDE3AMAPKAPK2 | |
| SCHEMBL1934823 | 0.79 | JAK2 (0.39) | KMOGSK3BMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332936-B1 | PYRIDINE COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL CO (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20110178132-A1 | PYRIDINE COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2332936-A1 | PYRIDINE COMPOUND AND USE THEREOF FOR PEST CONTROL | Sumitomo Chemical Company, Limited (JP) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178132-A1 | PYRIDINE COMPOUND AND USE THEREOF FOR PEST CONTROL | C5, PRDX1, PRDX4 | KMO 632/4885MPL 3986/4885PDE3B 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.